Crude Oil Moves Higher; RxSight Shares Plunge

U.S. equities traded higher on Wednesday, with the Nasdaq Composite leading gains, while European markets also advanced despite mixed performance across Asia. A key economic development was the U.S. crude oil inventories increasing by 7.070 million barrels, marking the largest weekly gain since January. Sectorally, communication services outperformed, while consumer staples lagged. Notable individual stock movements included Calidi Biotherapeutics surging over 350% on healthcare developments and RxSight plummeting 42% after significantly cutting its 2025 revenue guidance.

Analysis

The U.S. market demonstrated a risk-on sentiment, with the tech-heavy Nasdaq Composite's 0.62% gain leading broader indices higher, while European bourses also advanced. This occurred despite mixed results in Asia and a significant bearish signal from the energy sector, where U.S. crude oil inventories surged by 7.070 million barrels, the largest weekly increase since January. Sector-wise, this risk appetite was evident as communication services shares rose 1.1%, while defensive consumer staples stocks declined by 1%. The session was marked by extreme single-stock volatility driven by fundamental catalysts. On the positive side, Calidi Biotherapeutics (CLDI) soared 353% on developmental news, SU Group Holdings (SUGP) jumped 155% after securing an HK$88.5 million contract, and Evoke Pharma (EVOK) gained 171% following a U.S. patent allowance. Conversely, RxSight, Inc. (RXST) plummeted 42% after drastically cutting its 2025 revenue guidance from a range of $160M–$175M to $120M–$130M, signaling a severe deterioration in its business outlook. Other significant losers included Bitmine Immersion (BMNR) and Vertical Aerospace (EVTL), which fell 47% and 31% respectively due to capital raising activities, specifically a mixed shelf filing and a $60 million public offering, which create overhang from potential shareholder dilution.

Key Decisions for Investors

• Investors in RxSight (RXST) should immediately reassess their thesis, as the substantial 2025 revenue guidance cut to $120M–$130M indicates a critical negative shift in the company's growth trajectory and market position.
• Extreme caution is warranted for the day's high-flyers like Calidi Biotherapeutics (CLDI) and Evoke Pharma (EVOK); these parabolic, catalyst-driven moves are often unsustainable, and positions should be managed with strict risk controls to protect against potential reversals.
• The sharp declines in Bitmine Immersion (BMNR) and Vertical Aerospace (EVTL) highlight the dilutive impact of equity financing, and shareholders should scrutinize the use of proceeds and update their valuation models to account for the increased share count.
• The significant build in U.S. crude oil inventories, the largest since January, suggests potential weakness in underlying energy demand, a key risk factor to monitor for those with exposure to the energy sector, despite the minor daily uptick in oil prices.